Retatrutide UK: Availability, Legal Status and Timeline
Quick answer: Retatrutide is not available in the UK. It has no MHRA marketing authorisation, so no doctor can prescribe it — not on the NHS, not privately, not through an online pharmacy. A realistic UK approval window is 2028, with NHS access following a NICE appraisal from around 2029. Mounjaro, Wegovy, and the newly licensed oral semaglutide are the MHRA-approved options available now.
Can You Get Retatrutide in the UK?
No, through any route. Retatrutide holds no marketing authorisation from the MHRA, and it is not approved by the FDA or EMA either. It is an investigational medicine still in Phase 3 trials.
That has specific consequences under UK law. A GP cannot prescribe it. A private weight-management clinic cannot prescribe it. An online pharmacy cannot dispense it. There is no unlicensed-import route, because unlicensed importation requires a licensed product somewhere — and retatrutide is not licensed anywhere in the world. See what retatrutide is and how it works for the background.
The only legitimate access is clinical trial enrolment, listed on ClinicalTrials.gov and the ISRCTN registry.
The MHRA Pathway — and Why the UK Could Move Faster Than the EU
This is the part that distinguishes the UK timeline, and most coverage skips it.
Since leaving the EU regulatory system, the MHRA operates an International Recognition Procedure. Where a trusted regulator such as the FDA has already completed a review, the MHRA can rely on that assessment rather than duplicating it. The target is 67 working days — roughly three months — from accepted submission to decision.
The precedent for this is Eli Lilly’s own previous drug. Tirzepatide was approved by the FDA in May 2022 and by the MHRA in September 2022, a gap of four to five months. The MHRA then separately authorised it for weight management in November 2023.
There is a more striking recent example. In January 2026 the MHRA approved the higher 7.2 mg dose of Wegovy — the first regulator in the world to do so, ahead of the FDA. In June 2026 it licensed oral semaglutide, the first weight-loss tablet authorised in the UK, which reached private prescription in July.
The UK is not automatically behind the US on this class of drug. On two recent occasions it has been in front.
Because the MHRA route follows the FDA’s, the US timeline effectively sets the UK one — the US regulatory position is tracked and updated as milestones land.
One caveat: retatrutide’s triple-receptor mechanism is genuinely novel, and the dysesthesia signal seen in TRIUMPH-4 may draw more scrutiny than a familiar dual-agonist would. Recognition procedures work best for well-characterised mechanisms.
Realistic UK Timeline
| Stage | Expected timing |
|---|---|
| Remaining TRIUMPH Phase 3 readouts | Through late 2026 |
| FDA submission (Biologics License Application) | Q1 2027 (announced by Eli Lilly) |
| MHRA submission | 2027, within months of the FDA filing |
| Possible MHRA marketing authorisation | 2028 |
| Private UK prescribing | Immediately following authorisation |
| NICE technology appraisal | Following authorisation |
| Possible NHS availability | 2029 at the earliest |
Authorisation and NHS funding are separate stages, usually years apart
Sources: MHRA International Recognition Procedure guidance; NICE TA1026 (December 2024); Eli Lilly TRIUMPH programme announcements. Projected dates reflect regulatory precedent, not company guidance.
None of these dates are confirmed. Eli Lilly announced on 23 July 2026 that it will submit a Biologics License Application to the FDA in Q1 2027, but has not announced an MHRA filing date, and regulators can request additional data at any stage.
NHS Access and the Four-Nation Problem
MHRA authorisation and NHS availability are separate things, and the gap between them is usually years.
Authorisation means a drug can be lawfully prescribed. NHS funding requires a health technology assessment — and the UK runs four of them. NICE covers England, the Scottish Medicines Consortium covers Scotland, the All Wales Medicines Strategy Group covers Wales, and the Department of Health handles Northern Ireland. Outcomes and timings can differ between them.
The tirzepatide rollout shows what this looks like in practice. NICE published TA1026 in December 2024, and NHS England then phased access in cohorts. The first cohort, from June 2025, was restricted to adults with a BMI of 40 or above and at least four of five weight-related conditions.
That is the realistic template for retatrutide: authorisation first, private prescribing next, then a narrow initial NHS cohort expanding over years.
The Counterfeit Pen Problem
The gap between UK demand and zero legal supply has produced a substantial illegal market, and the MHRA has been actively dismantling parts of it.
Enforcement action against UK facilities producing counterfeit GLP-1 medicines has found pens containing insulin, saline, or unidentified substances rather than the labelled drug.
The insulin finding is the one that matters most. Insulin taken by someone who is not diabetic, without carbohydrate intake matched to the dose and without glucose monitoring, can cause severe hypoglycaemia — confusion, seizures, loss of consciousness. It is a medical emergency, and it can happen within hours.
Retatrutide is sold across UK sites in “pen” formats of 20 mg and 40 mg. No clinical trial has used anything resembling those quantities as a unit — Phase 3 maintenance doses were 4 mg, 9 mg, and 12 mg weekly. A pen labelled 40 mg does not correspond to any studied preparation, and identity cannot be verified by a buyer — why the products sold online cannot be verified.
If you have used a product sold as retatrutide and feel unwell, contact NHS 111. For severe symptoms — difficulty breathing, facial or throat swelling, collapse, or confusion you cannot account for — call 999.
What Is Licensed in the UK Right Now
| Medicine | Type | Trial weight loss | NHS | Private |
|---|---|---|---|---|
| Mounjaro (tirzepatide) | GLP-1 + GIP injection | 22.5% at 72 wks | Yes, restricted cohorts | Yes |
| Wegovy 7.2 mg (semaglutide) | GLP-1 injection | 20.7% at 72 wks | Specialist services | Yes |
| Wegovy pill (oral semaglutide) | GLP-1 daily tablet | 13.6% at 64 wks | Not yet | Yes |
| Saxenda (liraglutide) | GLP-1 daily injection | ~8% | Restricted | Yes |
| Retatrutide | Triple agonist | 28.3% at 80 wks | No | No |
Average trial weight loss, and what you can actually be prescribed
Figures come from separate trials with different populations and durations — TRIUMPH-1 at 80 weeks, SURMOUNT-1 at 72, STEP-UP at 72, OASIS 4 at 64 — so they are indicative rather than a like-for-like ranking. Retatrutide has no MHRA authorisation and cannot be prescribed in the UK.
Orlistat and Mysimba (naltrexone/bupropion) are also licensed, with considerably smaller effects.
UK private pricing varies by clinic and pharmacy. For the US picture and what retatrutide is likely to cost once approved, see US pricing and what to expect at launch.
Retatrutide vs Mounjaro
Mounjaro is the UK brand for tirzepatide, and it is the closest available comparison. Retatrutide adds a third receptor target — glucagon — to Mounjaro’s GLP-1 and GIP.
On trial data, retatrutide has produced larger average weight loss: 28.3% at 80 weeks in TRIUMPH-1 against 22.5% at 72 weeks for tirzepatide in SURMOUNT-1. But these are separate trials with different populations, durations, and reporting conventions. TRIUMPH-5, a direct head-to-head study, completes in December 2026 with results expected in 2027.
The practical comparison is less balanced than the efficacy one. Mounjaro is licensed, prescribable today, available on the NHS for eligible patients, and backed by years of real-world safety data. Retatrutide is none of those things and will not be for at least eighteen months. For the detail behind the efficacy figures, see the full comparison on trial data.
For trial results, safety data, dosing and regulatory tracking, browse the full retatrutide resource library.
Frequently Asked Questions
Is retatrutide available in the UK?
No. It has no MHRA marketing authorisation and cannot be prescribed on the NHS, privately, or through an online pharmacy.
Can you get retatrutide on the NHS?
No. NHS availability would require MHRA authorisation followed by a NICE technology appraisal, realistically not before 2029.
When will retatrutide be approved in the UK?
No date is confirmed. 2028 is the realistic window for MHRA authorisation. Eli Lilly has said it will file with the FDA in Q1 2027, and an MHRA submission would follow within months.
Can I buy retatrutide in the UK legally?
No. Sites selling it as a research peptide operate outside regulatory oversight. The MHRA has taken enforcement action against UK facilities producing counterfeit GLP-1 medicines, some containing insulin or saline instead of the labelled drug.
Is retatrutide better than Mounjaro?
On trial data it has produced larger weight loss — 28.3% versus 22.5% — but from separate trials rather than a direct comparison. TRIUMPH-5 reports in 2027. Mounjaro is licensed and available now; retatrutide is not.
What is a retatrutide pen?
Trials used weekly subcutaneous injection at 4 mg, 9 mg, or 12 mg maintenance doses. The 20 mg and 40 mg “pens” sold on UK sites correspond to no studied preparation and are not licensed products.
Will the UK approve retatrutide before the US?
Possible but not likely for a first authorisation. The MHRA’s International Recognition Procedure is designed to follow a trusted regulator’s review, though the UK did approve Wegovy 7.2 mg ahead of the FDA in January 2026.
Sources
ClinicalTrials.gov: TRIUMPH-1 (NCT05929066), TRIUMPH-5 (NCT06662383).
MHRA. International Recognition Procedure guidance.
NICE. TA1026, tirzepatide for managing overweight and obesity, December 2024.
MHRA. Authorisation of semaglutide 7.2 mg, January 2026; oral semaglutide, June 2026.
Eli Lilly. TRIUMPH-1 topline results, May 2026; full data ADA 86th Scientific Sessions, June 2026.
Eli Lilly. SURMOUNT-1 results, April 2022.